Somatuline Depot Side Effects
Generic name: lanreotide
Medically reviewed by Drugs.com. Last updated on Jul 25, 2022.
Note: This document contains side effect information about lanreotide. Some dosage forms listed on this page may not apply to the brand name Somatuline Depot.
Applies to lanreotide: subcutaneous solution.
Serious side effects of Somatuline Depot
Along with its needed effects, lanreotide (the active ingredient contained in Somatuline Depot) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking lanreotide:
More common
- Blurred vision
- chest pain or discomfort
- dizziness
- gaseous abdominal or stomach pain
- headache
- lightheadedness, dizziness, or fainting
- nervousness
- pale skin
- pounding in the ears
- recurrent fever
- slow, fast, or irregular heartbeat
- stomach fullness
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- yellow eyes or skin
Incidence not known
- Bloating
- chills
- clay-colored stools
- confusion
- constipation
- cough
- dark urine
- diarrhea
- difficulty swallowing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fat in the stool
- fever
- hives, itching, skin rash
- indigestion
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- loss of appetite
- nausea
- pains in the stomach, side, or abdomen, possibly radiating to the back
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- severe nausea or vomiting
- stomach pain or cramps
- sudden loss of weight
- sweating
- tightness in the chest
- unusual drowsiness, dullness, or feeling of sluggishness
- vomiting
Other side effects of Somatuline Depot
Some side effects of lanreotide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Difficulty having a bowel movement
- difficulty with moving
- excess air or gas in the stomach or bowels
- feeling of fullness
- inflammation, itching, lumps, or pain at the injection site
- muscle pain or stiffness
- pain in the joints
- passing gas
- weight loss
For Healthcare Professionals
Applies to lanreotide: subcutaneous solution.
General
The most common adverse events were gastrointestinal disorders, cholelithiasis, and injection site reactions.[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (up to 65%), abdominal pain (34%), vomiting (19%), flatulence (14%), nausea (11%), loose stools
Common (1% to 10%): Constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia
Uncommon (0.1% to 1%): Pancreatitis, feces discolored
Frequency not reported: Steatorrhea[Ref]
In one of the studies, diarrhea, abdominal pain, and flatulence increased as the dose increased.[Ref]
Hepatic
Very common (10% or more): Cholelithiasis (27%), bladder sludge (20%), new cholelithiasis
Common (1% to 10%): ALT increased, AST abnormal, ALT abnormal, blood bilirubin increased, biliary dilatation
Uncommon (0.1% to 1%): AST increased, blood alkaline phosphatase increased, blood bilirubin abnormal
Frequency not reported: Cholecystitis
Postmarketing reports: Steatorrhea, pancreatitis[Ref]
Cardiovascular
Very common (10% or more): Bradycardia (18%), hypertension (14%)
Common (1% to 10%): Sinus bradycardia
Uncommon (0.1% to 1%): Other cardiac adverse drug reactions[Ref]
Local
Very common (10% or more): Application site disorder (injection site mass/pain/reaction/inflammation/ nodule/pruritus, 30%)
Postmarketing reports: Persisting induration, injection site abscess[Ref]
Metabolic
Very common (10% or more): Dysglycemia (hypoglycemia, hyperglycemia, diabetes, 14%), weight decrease (11%)
Common (1% to 10%): Blood glucose increased, glycosylated hemoglobin increased
Uncommon (0.1% to 1%): Blood sodium decreased, diabetes mellitus aggravated[Ref]
Hematologic
Very common (10% or more): Anemia (14%)[Ref]
Musculoskeletal
Very common (10% or more): Musculoskeletal pain (19%), arthralgia (11%)[Ref]
Nervous system
Very common (10% or more): Headache (16%)
Common (1% to 10%): Dizziness
Postmarketing reports: Dysautonomia[Ref]
Respiratory
Common (1% to 10%): Dyspnea[Ref]
Psychiatric
Common (1% to 10%): Depression
Uncommon (0.1% to 1%): Insomnia[Ref]
Other
Common (1% to 10%): Fatigue
Uncommon (0.1% to 1%): Hot flush, asthenia
Postmarketing reports: Malaise[Ref]
Immunologic
Common (1% to 10%): Anti-lanreotide (the active ingredient contained in Somatuline Depot) antibodies[Ref]
Hypersensitivity
Frequency not reported: Allergic reactions (including angioedema, anaphylaxis, and hypersensitivity)[Ref]
Dermatologic
Common (1% to 10%): Alopecia, hypotrichosis[Ref]
Endocrine
Rare (less than 0.1%): Clinical hypothyroidism
Frequency not reported: Slight decreases in thyroid function[Ref]
More about Somatuline Depot (lanreotide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: somatostatin and somatostatin analogs
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Product Information. Somatuline Depot (lanreotide). Ipsen Inc. 2007.
3. Cerner Multum, Inc. Australian Product Information.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.